Real-World Efficacy and Safety of Escalation to Weekly Adalimumab for Chronic Non-Infectious Uveitis: A Multicenter Study Involving Pediatric and Adult Patients
Weekly ADA is effective and safe for controlling NIU when bi-weekly dosing is insufficient. Combining ADA with DMARDs enhances outcomes and reduce uveitis attacks. Poor preADA visual acuity may suggest resistance to biologics. Prospective studies should validate these findings, explore anti-ADA antibody development, and assess how DMARD addition affects immunological parameters and treatment efficacy.
Authors
- Burak Tanyıldız (ORCID: https://orcid.org/0000-0001-8245-8389)
- Nilüfer Zorlutuna Kaymak (ORCID: https://orcid.org/0000-0002-9673-824X)
- Kübra Özdemir Yalçınsoy (ORCID: https://orcid.org/0000-0002-3352-9547)
- Merve İnanç (ORCID: https://orcid.org/0000-0002-9930-7680)
- Pınar Özdal (ORCID: https://orcid.org/0000-0002-5714-7172)
- Murat Oklar (ORCID: https://orcid.org/0000-0001-5254-0613)
Institutions
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- Ulucanlar Göz Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1080/09273948.2025.2456637
- Citations
- 6
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 10.24